The FDA released a video updating information regarding atypical femur fractures that have been associated with the use of bisphosphonates to treat osteoporosis.  (Fosamax, Actonel, Boniva, Atelvia, Reclast, and their generic equivalents.)

Click here to watch the FDA Video

Among the FDA recommendations to medical professionals are:

• be aware of the possibility of atypical femur fractures in patients taking bisphosphonates

• consider periodically re-evaluating whether continued bisphosphonate therapy is needed, especially in patients who have been treated for more than five years. Periodic reevaluation is recommended because the fracture reduction efficacy of these drugs has not been established, and the optimal duration of use is uncertain.

• discuss the benefits and risks of these drugs with patients, and instruct them to seek medical attention if they experience new groin or thigh pain, which may be described as dull or aching. This pain can occur weeks or months before a complete fracture occurs.

Click here for more information about the Brandi Law Firm Fosamax Attorneys.